Marc-Oliver Grimm, MD, professor, chairman, Division of Urology, Jena College Hospital, discusses the unmet wants for sufferers who progress to metastatic castration-resistant prostate most cancers (mCRPC) following therapy with an androgen receptor pathway inhibitor (ARPI), androgen deprivation remedy (ADT), and chemotherapy within the hormone-sensitive setting. He additionally highlights future steps of analysis following a post-hoc evaluation of the part 3 ARASENS trial (NCT02799602).
The evaluation sought to guage post-progression survival in sufferers with metastatic hormone-sensitive prostate most cancers (mHSPC) who obtained darolutamide (Nubeqa) together with ADT and docetaxel in contrast with those that obtained placebo plus ADT and docetaxel.
The evaluation, which was offered on the 2024 ASCO Annual Assembly, revealed that darolutamide plus ADT and docetaxel elevated total survival in contrast with placebo plus ADT and docetaxel, and this routine additionally delayed the time to development to mCRPC. Following development, sufferers handled with the darolutamide routine had related survival outcomes no matter subsequent remedy choice. Nevertheless, sufferers who obtained the placebo routine skilled extended survival when subsequent therapy included an ARPI vs non-ARPI therapies, which had been primarily chemotherapy.
Grimm notes that outcomes from the post-hoc evaluation spotlight a persisting want for more practical therapy choices for sufferers who progress to mCRPC following therapy with an ARPI and chemotherapy. Further evaluation of the ARASENS trial is ongoing.
